A comparative study of the disc diffusion method with the broth microdilution and Etest methods for viroconazole susceptibility testing of Aspergillus spp

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 5, 2004, Pages 739-742

  Serrano, M C ^a   Ramirez M ^a   Morilla, D ^a   Valverde, A ^a   Chavez M ^a   Espinel Ingroff, A ^b   Claro, R ^c   Fernandez A ^a   Almeida, C ^a   Martín Mazuelos, Estrella ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

Antifungals; Susceptibility tests

Indexed keywords

METHYLENE BLUE; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; ASPERGILLUS; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; DIFFUSION; DILUTION; FUNGAL STRAIN; FUNGUS ISOLATION; INTERMETHOD COMPARISON; LIQUID CULTURE; NONHUMAN; RHIZOMUCOR;

ANTIFUNGAL AGENTS; ASPERGILLUS; CULTURE MEDIA; DIFFUSION; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; QUALITY CONTROL; TRIAZOLES;

EID: 2542441670     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh172     Document Type: Article

References (31)

1. Annaise, E. (1992). Opportunistic mycosis in the immunocompromised host: experience at a cancer center and review. Clinical Infectious Diseases 14, S43-53.
2. Denning, D. W. (1996). Therapeutic outcome in invasive aspergillosis Clinical Infectious Diseases 23, 608-15.
3. Denning, D. W. (1998). Invasive aspergillosis. Clinical Infectious Diseases 26, 781-805.
4. Iwen, P. C., Rupp, M. E., Langnas, L. N. et al. (1999). Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of literature. Clinical Infectious Diseases 26, 1092-7.
5. Chumpitazi, B. F., Pinel, C., Lebeau, B. et al. (2000). Aspergillus fumigatus antigen detection in sera from patients at risk for invasive aspergillosis. Journal of Clinical Microbiology 38, 438-43.
6. Patterson, T. F., Kirkpatrick, W. R., White, M. et al. (2000). Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine 79, 250-60.
7. Pfaller, M. A., Messer, S. A., Houston, A. et al. (2000). Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media. Journal of Clinical Microbiology 38, 3715-7.
8. Lin, S. J., Schranz, J. & Tentsch, S. M. (2001). Aspergillus case-fatality rate: systematic review of the literature. Clinical Infectious Diseases 32, 358-66.
9. Patterson, T. F. (2002). New agents for treatment of invasive aspergillosis. Clinical Infectious Diseases 35, 367-9.
10. Marco, F., Pfaller, M. A., Messer, S. et al. (1998). In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrobial Agents and Chemotherapy 42, 161-3.
11. Arikan, S., Lozano-Chiu, M., Paetznick, V. et al. (1999). Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against isolates of Aspergillus and Fusarium species. Journal of Clinical Microbiology 37, 3946-51.
12. Chávez, M., Bernal, S., Valverde, A. et al. (1999). In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients. Journal of Antimicrobial Chemotherapy 44, 697-700.
13. Pfaller, M. A., Jones, R. N., Doern, G. V. et al. (1999). International surveillance of bloodstream infections due to Candida species in the European SENTRY program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. Diagnostic Microbiology and Infectious Disease 35, 19-25.
14. Uzun, O., Arikan, S., Kocagoz, S. et al. (2000). Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading. Diagnostic Microbiology and Infectious Disease 38, 101-7.
15. Serrano, M. C., Valverde, A., Chávez, M. et al. (2003). In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergillus spp. Diagnostic Microbiology and Infectious Disease 45, 131-5.
16. Cuenca-Estrella, M., Rodriguez-Tudela, J. L., Mellado, E. et al. (1998). Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. Journal of Antimicrobial Chemotherapy 42, 531-3.
17. Verweij, P. E., Mensink, M. & Rijs, A. J. (1998). In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. Journal of Antimicrobial Chemotherapy 42, 389-92.
18. Johnson, E. M., Szekely, A. & Warnock. D. W. (1998). In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. Journal of Antimicrobial Chemotherapy 42, 741-5.
19. Abraham, O. C., Manavathu, E. K., Cutright, J. L. et al. (1999). In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B. Diagnostic Microbiology and Infectious Disease 33, 7-11.
20. Manavathu, E. K, Cutright, J. L. & Loebenberg, D. (2000). A comparative study of the in-vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). Journal of Antimicrobial Chemotherapy 42, 229-34.
21. Pfaller, M. A., Messer, S. A., Hollis, R. J. et al. (2002). Antifungal activities of posaconazole, ravuconazole and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrobial Agents and Chemotherapy 46, 1032-7.
22. Perfect, J. R., Marr, K. A., Walsh, T. J. et al. (2003). Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clinical Infectious Diseases 36, 1122-31.
23. Barry, A. L. & Brown, S. D. (1996). In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrobial Agents and Chemotherapy 40, 1948-9.
24. Kronvall, G. & Karlsson, I. (2001). Fluconazole and voriconazole multidisk testing of Candida species for disk test calibration and MIC estimation. Journal of Clinical Microbiology 39, 1422-8.
25. Murphy, M., Bernard, E. M., Ishimaru, T. et al. (1997). Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy 41, 696-8.
26. Espinel-Ingroff, A. & Rezusta, A. (2002). Etest method for testing susceptibilities of Aspergillus spp. to new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method. Journal of Clinical Microbiology. 40, 2101-7.
27. Pfaller, M. A., Diekema, D. J., Messer, S. A. et al. (2003). Activities of fluconazole and voriconazole against 1586 recent clinical isolates of Candida species determined by broth microdilution, disc diffusion, and Etest methods: report from the ARTEMIS global antifungal susceptibility program 2001. Journal of Clinical Microbiology 41, 1440-6.
28. Matar, M. J., Ostrosky-Zeichner, L., Paetznick, V. L. et al. (2003). Correlation between Etest, disc difusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrobial Agents and Chemotherapy 47, 1647-51.
29. National Committee for Clinical Laboratory Standards. (2002). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium-Forming Filamentous Fungi: Proposed Standard M38-A. NCCLS, Wayne, PA, USA.
30. Szekely, A., Johnson, E. M. & Warnock, D. W. (1999). Comparison Etest and Broth methods for antifungal drug susceptibility testing of molds. Journal of Clinical Microbiology 37, 1480-3.
31. National Committee for Clinical Laboratory Standards. (2003). Method for Antifungal Disk Diffusion Susceptibility Testing of Yeast: Proposed Guideline M44-P. NCCLS, Wayne, PA, USA.